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Abstract
Foot-and-mouth disease (FMD) is an acute, highly contagious viral disease of domestic and
wild cloven-hoofed animals, caused by FMD virus (FMDV). An FMD outbreak can cause
major production losses and have significant implications for trade. Vaccination can assist in
controlling the disease, and emergency vaccination using high antigen payload vaccines
(>6 PD50/dose) is considered an important control approach in the event of an outbreak. In
recent years there has been a divergence of serotype A viruses in South East Asia (SEA)
into several distinct genetic and antigenic clusters. Numerous variants were found to poorly
match serotype A vaccines commonly included in international antigen banks. This study
examined the ability of single vaccination with high-potency monovalent A22 IRQ vaccine to
protect sheep following challenge with the A/VIT/15/2012 strain, just four days following vac-
cination. The vaccine proved effective at limiting clinical disease but did not prevent
infection.
Introduction
Foot-and-mouth disease (FMD) is a highly infectious disease that affects ruminants and pigs,
caused by FMD virus (FMDV), a small, positive-sense RNA virus in the Genus Aphthovirus,
Family Picornaviridae. Cattle, pigs, sheep and goats are the livestock species that play an
important role in the epidemiology of FMD in many parts of the world, and sheep have been
central to the spread of infection in numerous outbreaks [1, 2]. This spread is facilitated by
cases often going undetected, as clinical signs of FMD in sheep are frequently mild or inappar-
ent. Sheep, like other ruminants, can also become persistently infected with FMDV [3, 4].
Vaccination is often used to assist in controlling the disease, however, there is little or no
cross-protection between the seven different serotypes, and varied cross-protection between
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different strains of the same serotype [5–8]. Emergency vaccination using high antigen payload
vaccines (>6 protective dose (PD)50/dose) is considered an important control approach in the
event of an outbreak in some FMD-free countries, reducing the extent of FMDV excretion,
limiting the possibility of transmission and potentially minimising the duration and intensity
of an outbreak. Previous studies have shown high-potency vaccination to be effective at pro-
tecting animals challenged as early as four days post-vaccination (dpv) [9–13].
Serotype A is one of the most genetically and antigenically diverse of the FMDV serotypes
and new antigenic variants emerge frequently [14, 15]. Over the last ten years there has been a
divergence of serotype A viruses in South East Asia (SEA) into several distinct genetic and
antigenic clusters. Variants from Vietnam in 2012 were found to match poorly (poor r1 values
in in vitro vaccine matching studies) with the serotype A vaccines commonly included in inter-
national antigen banks (WRL, Pirbright).
The objective of this study was to determine if a single vaccination with an emergency
monovalent A22 IRQ vaccine with high antigen payload (>6 PD50/dose) can confer protection
in sheep and prevent the development of persistent infection following direct-contact chal-
lenge with the heterologous A/VIT/15/2012 strain, which belongs to the SEA97 lineage, in an
emergency vaccination scenario. To reflect an outbreak situation, where the time between vac-
cination and challenge may be minimal, vaccinated animals were challenged just four days fol-




This study was approved by the Canadian Centre for Human and Animal Health Animal Care
Committee (AUD# C-14-002) and Australian Animal Health Laboratory’s Animal Ethics
Committee (AEC 1680) and performed in strict accordance with the recommendations in the
Canadian Council for Animal Care Guidelines and the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes.
Animals
Thirty Rideau Arcott/Ile de France rams aged between 6 and 12 months (approximately 40 kg)
were used. All animals were housed in the BSL3 animal facility at the National Centre for For-
eign Animal Disease (NCFAD), Winnipeg, Canada. The sheep were divided into three groups:
unvaccinated, coronary band (CB) inoculated donor sheep (n = 18); vaccinated contact-chal-
lenged (VC) sheep (n = 6); and unvaccinated contact-challenged (UC) sheep (n = 6).
Vaccination
The VC sheep were vaccinated with one full sheep dose (1 ml) of high antigen payload (>6
PD50/dose) FMDV A22 IRQ double-oil emulsion vaccine, formulated by Merial Animal
Health, Pirbright, UK, and administered intramuscularly in the neck region above the left
shoulder. Vaccination was given 4 days prior to challenge.
Challenge virus
The challenge virus, A/VIT/15/2012, was isolated from pigs in Vietnam in 2012 and belongs to
the Asia topotype (SEA-97 lineage). After original isolation on baby hamster kidney cells, the
virus was passaged through cattle. Inoculum prepared from lesion material was titrated in two
cattle by tongue titration and the cattle infectious dose (CID50) was calculated to be ~10
8/ml.
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The r1 value in a virus neutralisation test (VNT) vaccine matching assay was 0.17 against A22
IRQ (WRL, Pirbright).
Experimental design
Eighteen donor sheep were each inoculated intradermally into the CB with 5 log10 CID50 of
virus in a volume of 0.1 ml. The VC and UC sheep were challenged by continuous direct con-
tact with the donor sheep, starting 4 hrs after their inoculation (designated as 0 days post-chal-
lenge (dpc)). The sheep were arranged into groups of five, housed in six separate rooms, with
one VC sheep, one UC sheep and three directly inoculated donor sheep per room. The sheep
distribution per room is described in Table 1.
Monitoring and sample collection
The sheep were monitored for the development of clinical signs such as pyrexia, lameness and
development of vesicles with rectal temperatures and clinical scores recorded daily to 14 dpc.
Sheep showing elevated temperatures (>40.5˚C) were considered as having pyrexia. Clinical
Table 1. Allocation of sheep per room and day post-challenge each animal was euthanized.
Room Sheep No. Challenge Vaccinated Day Euthanized
1 7 Contact Yes 9
13 Contact No 9
19 CB No 9
20 CB No 9
21 CB No 9
2 8 Contact Yes 35
14 Contact No 10
22 CB No 9
23 CB No 9
24 CB No 9
3 9 Contact Yes 35
15 Contact No 12
25 CB No 9
26 CB No 9
27 CB No 9
4 10 Contact Yes 35
16 Contact No 21
28 CB No 9
29 CB No 9
30 CB No 9
5 11 Contact Yes 35
17 Contact No 21
31 CB No 8
32 CB No 9
33 CB No 9
6 12 Contact Yes 35
18 Contact No 12
34 CB No 9
35 CB No 9
36 CB No 9
https://doi.org/10.1371/journal.pone.0195302.t001
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scores were calculated as follows: per foot, a score of 1 if a lesion developed in one location
(CB, interdigital cleft or heel pad) and a score of 2 if lesions developed in two or more loca-
tions; 1 each for oral (tongue, gums or dental pad) lesions, 1 if visibly lame/slow to rise. The
maximum score was 10.
Clinical samples were collected from the donor and in-contact animals at regular intervals
for 35 days. Blood in EDTA tubes for RT-qPCR and clotted blood for serology were collected
at -4 dpc, daily between 0 and 14 dpc and then weekly to 35 dpc. Small sterile cotton buds were
used to collect nasal and saliva secretions at the same time points. Rectal swabs were collected
daily between 0 and 4 dpc. All swabbing was performed in duplicate and swabs placed in tubes
containing 500 μl of phosphate buffered saline (PBS) for RT-qPCR or 500 μl of Dulbecco’s
modified Eagle’s medium (DMEM) containing 0.04 M HEPES and antibiotics (catalog no.
15240062; Gibco) for virus isolation. Oro-pharyngeal fluid (OPF) was collected at -1, 7, 9, 14,
21, 28 and 35 dpc, using a small probang sampling cup and mixed with 2 ml DMEM contain-
ing 0.04 M HEPES. For animals that were euthanized on day 12, samples were collected at this
time point instead of day 14. At the time of sacrifice, sheep were sedated with 2% Xylazine at
0.67 ml/100 Kg body weight and euthanized by intravenous injection of sodium pentobarbital
(100mg/kg IV).
Virus isolation
Oro-pharyngeal fluid samples were examined for the presence of live virus by inoculation onto
αVβ6-expressing porcine kidney (LFBK-αVβ6) cells [16, 17] grown in 24-well cell culture
trays, and incubated for 30 mins at 37˚C. The cells were washed with PBS and overlayed with
DMEM containing 5% foetal bovine serum and antibiotics (catalog no. 15240062; Gibco),
then examined for cytopathic effect after 24 and 48 hrs incubation at 37˚C with 5% CO2. If no
cytopathic effect was observed, a blind passage followed. All supernatants from positive wells
were tested using an FMDV antigen enzyme-linked immunosorbent assay (ELISA) and A22
IRQ reagents [18].
Detection of FMDV RNA by RT-qPCR
The amount of viral RNA in whole blood, OPF and nasal, oral and rectal swab samples was
quantified by a TaqMan RT-qPCR assay as described previously [11]. Samples with a Ct >40
(equivalent to 1 x 103.5 copies RNA/ml blood or 1 x 103.2 copies RNA/swab) were considered
negative.
Determination of neutralising antibody titre
Heat inactivated (56˚C, 30 min) serum samples were used for VNT on swine kidney (IBRS2)
cells using A/VIT/15/2012 and A22 IRQ viruses previously adapted to IBRS2 cells by passaging
5 times. Titres1.2 log10 (1:16) were considered positive (OIE Manual of Diagnostic Tests
and Vaccines for Terrestrial Animals).
Detection of antibodies to non-structural and structural proteins by ELISA
Sera were tested for the presence of antibodies against viral non-structural proteins (NSP) by
an NCFAD in-house competitive ELISA (3ABC-ELISA) [18] and for the presence of antibod-
ies against FMDV type A structural proteins (SP) by A-serotype specific competitive ELISA
(cELISA) using reagents homologous to A22 IRQ and a protocol similar to that described by
Mackay [19].
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Statistical analysis
The total viral excretion of each donor was estimated by calculating the sum of the integral of
the curve of its daily oral and nasal viral load, as estimated by the RT-qPCR. Estimates were
calculated for the first 6 days of the experiment, as this is noted in the literature as the time
sheep are excreting most virus [20]. The total viral load for this time period for each room
used in the infection study was graphed using boxplots, and an assessment of whether or not
there were significant differences between the rooms was tested using the Kruskal-Wallis non
parametric One-Way ANOVA by Ranks test.
As an estimate of the capacity of vaccination to prevent overt clinical disease we used
McNemar’s test on the 2 x 2 table of vaccination and disease status, with animals being
matched by their room and any animal with a score1 being classified as overtly diseased, or
else a classification of not overtly diseased.
To determine the median time for seroconversion of the donor and two in-contact groups
of sheep we used a Kaplan-Meier non-parametric time-to-event analysis. Right censoring was
enabled to allow for sheep that were euthanized before seroconversion had occurred. The start
time for the estimates was the day of inoculation/contact. To test for significant differences in
the time to seroconversion for the vaccinated and non-vaccinated in-contact sheep, we used a
log-rank test.
All analyses were done using R version 3.2.4 (https://www.r-project.org/). To determine the
integral of the daily viral load plots we used the “trapz” function of the “pracma” library. For
the Kruskal-Wallis test we used the “kruskal.test” function, for the McNemar’s test we used
“mcnemar.test” (with the continuity correction being applied). All of these functions belong to
the core R “stats” library. For the calculation of the median times of sero-conversions and for
the log-rank test, the “survfit” and “survdiff” functions from the “survival” library. Comparison
of virus excretion between the vaccinated and unvaccinated contacts were performed using
ANOVA with Single Factor and Fisher’s Exact Test.
Results
Donor sheep
Clinical signs and viraemia. This study comprised six replicate rooms with three donor
sheep and one VC and one UC sheep per room (Table 1). The clinical scores and FMDV RNA
load in blood, nasal swabs and oral swabs for each donor sheep are shown in S1 Fig. All CB
inoculated donor animals developed generalised FMD with multiple lesions on the feet,
mouth and tongue as early as 2 days post-challenge (dpc). On average, the rectal temperatures
of the sheep in the donor group were elevated with pyrexia recorded in 14 of the 18 sheep
between 1 to 9 dpc. Sheep 31 developed severe clinical disease with extensive lesions on all feet
and was euthanized for ethical reasons at 8 dpc. At 9 dpc, severe clinical signs including necro-
sis and hoof sloughing were also observed in sheep 24, 32 and 36. As these sheep required
euthanasia, the decision was made to cull all donors on this day to retain equivalence between
the rooms.
No viraemia was detected in sheep 20 or 29. In most other donor sheep viraemia lasted
three or four days (S1 Fig). However, for sheep 23 and 31 viraemia persisted for five days.
Virus was isolated on at least one day from the blood of all animals that were positive in RT-
qPCR, except sheep 28 and 35.
Virus in nasal and oral secretions. Nasal and oral swab samples from most donor
sheep were positive for FMDV RNA from as early as 1 dpc, and in some animals up to 9
dpc, with viral loads generally decreasing from 4–6 dpc (S1 Fig). Most animals were
Efficacy of emergency high payload FMDV vaccine against heterologous challenge in sheep
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positive in nasal swab samples for four or more consecutive days, and in oral swab samples
for three or more consecutive days. Sheep 28 had only one positive oral swab sample at 5
dpc, and all samples from sheep 29 were negative. Rectal swabs from all sheep were nega-
tive on all days tested.
The amount of virus detected in nasal and oral secretions can reflect the amount of virus
excreted, and subsequently the level of challenge to the in-contact sheep. The Kruskal-Wallis
analysis of total viral load in nasal and oral swabs from each group of three donor sheep indi-
cated no significant difference between the rooms over the first 6 dpc (p = 0.1148; Fig 1).
Oropharyngeal fluid samples from all donor sheep were positive for FMD virus and/or viral
RNA at 7 and/or 9 dpc (when all donors were euthanized), with the exception of sheep 20 and
29 (data not shown).
Immune response. All of the donors seroconverted to the challenge virus (A/VIT/15/
2012) by 5 dpc (Fig 2A). The neutralising antibody titres to the vaccine strain virus (A22 IRQ)
were lower overall compared to the challenge virus (A/VIT/15/2012), with one sheep negative
at 5 dpc. The higher VN titres to the challenge strain compared to the vaccine strain reflects
the r1 values. In ELISA, the median time to seroconversion, as assessed by the Kaplan-Meier
time to event analysis, was 4 days (95% CL: 4, 4) for the structural proteins (Fig 2B) and 7 days
(95% CL: 6, 7) for the NSP (Fig 2C).
Fig 1. Box plot of accumulated viral RNA loads in NS and OS from the three donor sheep per room over the first 6 dpc.
https://doi.org/10.1371/journal.pone.0195302.g001
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Contact sheep
Clinical signs and viraemia. Five of six VC sheep were protected from clinical disease
(Fig 3A). Only one (sheep 7) developed systemic FMD with a lesion on the right-hind heel pad
from 3 dpc. An interdigital lesion developed on the same foot by 5 dpc, followed by signs of
hoof sloughing at 9 dpc. Consequently this animal was euthanized for ethical reasons. The
majority of the VC sheep were not pyrexic with only sheep 7 having a rectal temperature above
40.5˚C at 5 dpc.
Fig 2. (A) Average neutralising antibody titres of the donor sheep sera to the vaccine virus (A22 IRQ) and the
challenge virus (A/VIT/2012). Values represent Log10 of the reciprocal of the highest dilution of serum that was able to
neutralise either 100 TCID50 of A22 IRQ or A/VIT/2012. The assay cut off was 0.9, titres1.2 are considered positive.
Time to seroconversion plots estimated by the Kaplan-Meier method for the donor sheep (B) for the structural protein
ELISA; and (C) for the non-structural protein ELISA. The dotted lines are the estimated 95% confidence limits.
https://doi.org/10.1371/journal.pone.0195302.g002
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Five of the six UC sheep developed systemic FMD (Fig 3B) with lesions on the feet and
gums appearing between 6 and 12 dpc. Sheep 13 was euthanized on day 9 in line with ethical
requirements for companionship, as the other sheep in this room had reached ethical end-
point. Sheep 14 developed severe disease on both hind feet and was euthanized on day 10. At
12 dpc, sheep 15 and 18 were euthanized for ethical reasons, followed by sheep 16 at 21 dpc.
The final UC sheep (sheep 17) was also euthanized on this day to retain equivalence, however,
no lesions were observed on necropsy. Rectal temperatures above 40.5˚C were recorded for
sheep 13–16 between 7 and 12 dpc, and for sheep 18 on 11 dpc.
Only one VC sheep (sheep 7, the same sheep that had lesions) was viraemic, with FMDV
RNA detected in the blood at 4 and 5 dpc (Fig 3A). However, virus was not isolated from any
of these RNA positive blood samples, despite RNA levels being comparable to that observed in
the donor sheep. This is likely due to the presence of neutralising antibodies from vaccination.
FMDV RNA was detected in the blood of five of the six UC sheep between 5 and 12 dpc (Fig
3B), and virus was isolated from sheep 14 at 5 dpc and 16 at 12 dpc. No viraemia was detected
in sheep 17 at any time point.
Analysis of the presence of clinical disease (or not) for the room-paired sheep using McNe-
mar’s test showed no significant difference between the VC and UC animals (p = 0.134).
Virus in nasal and oral secretions. FMDV RNA was detected in nasal swabs from sheep
7 from 5 to 8 dpc and in oral swabs between 2 and 7 dpc (Fig 3A). Sheep 11 and 12 were also
positive for FMDV RNA in nasal and oral swab samples, however only on one or two sampling
days. All other nasal and oral swab samples from the vaccinated sheep were negative.
Fig 3. Disease dynamics in VC (A) and UC (B) sheep. FMDV RNA detection in blood (red), nasal (green) and oral (blue) swabs was performed using RT-qPCR, and is
presented as log10 genome copy numbers/ml blood or swab. Clinical score is a cumulative index of FMD lesion distribution and clinical signs, where the maximum
score is 10.  = animal euthanized.
https://doi.org/10.1371/journal.pone.0195302.g003
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Nasal swab samples from UC sheep 13–16 were FMDV RNA positive on at least one day
between 6 and 10 dpc, and oral swab samples from three UC sheep (13, 14 and 18) were posi-
tive on at least one day between 5 and 9 dpc. Sheep 17 was negative in all samples from all days
(Fig 3B).
Analysis of virus RNA levels in the nasal and oral secretions between groups indicated no
significant difference between VC and UC sheep (oral secretions: p = 0.24 and p = 0.30; and
nasal secretions: p = 0.54 and 0.62, by ANOVA with Single Factor and Fisher’s Exact Test,
respectively).
Oropharyngeal fluid samples from five VC sheep were FMDV RNA positive during the
acute phase of infection (7–9 dpc) and one of these, sheep 12, was positive in all samples to 35
dpc. Virus was isolated from the same five sheep between 7 and 14 dpc and from sheep 11 and
12 at 21, 28 and 35 dpc, suggesting these two animals were persistently infected (Table 2). The
OPF from sheep 9 was not FMDV positive at any stage.
FMDV and/or FMDV RNA was detected in the OPF samples from five UC sheep between
7 and 14 dpc (Table 2). All samples from sheep 17 were negative.
Immune response. At the time of challenge, two VC sheep had detectable neutralising
antibodies to FMDV A22 IRQ, though at levels considered negative (titre of 1.08). The remain-
ing VC sheep had no detectable neutralising antibodies, and all were negative for neutralising
antibodies to FMDV A/VIT/15/2012 (Fig 4A). Five VC sheep seroconverted to FMDV A22
IRQ with neutralising antibodies by 5 dpc and the remaining sheep by 9 dpc, however against
the challenge strain, only three animals were positive at 5 dpc, and the remainder by 9 dpc. In
the VC group, the average titres against the vaccine strain were higher than against the chal-
lenge virus at 5 dpc, however from 9 dpc neutralising titres to the two viruses were
comparable.
Two out of six UC sheep seroconverted to FMDV A/VIT/15/2012 with neutralising anti-
bodies by 9 dpc and a further three by 14 dpc (Fig 4A). The neutralising antibody titres against
the vaccine strain were lower overall in the UC sheep and sheep 15 did not reach a level con-
sidered positive against this virus at the time of euthanasia (12 dpc). Sheep 17 did not have
Table 2. Detection of FMDV in probang samples from vaccinated in-contact transmission sheep (VC) and unvaccinated in-contact transmission sheep (UC).
Reported as detection by VI/RT-qPCR.
Group Sheep No. Days Post-challenge
-4 7 9 12/14 21 28 35
VC 7 -/- +/- +/5.1a nd nd nd nd
8 -/- -/- -/- +/4.9 -/- -/- -/-
9 -/- -/- -/- -/- -/- -/- -/-
10 -/- +/5.2 -/- -/- -/- -/- -/-
11 -/- +/6.8 +/10.5 -/- +/3.4 +/- +/3.3
12 -/- +/5.5 +/4.3 +/4.2 +/4.0 +/4.0 +/4.0
UC 13 -/- +/4.3 -/4.1 nd nd nd nd
14 -/- +/- +/4.4 nd nd nd nd
15 -/- -/- -/- +/4.9 nd nd nd
16 -/- -/- +/- +/- nd nd nd
17 -/- -/- -/- -/- nd nd nd
18 -/- +/- -/- -/3.4 nd nd nd
+ = VI positive; - = VI or RT-qPCR negative; nd–not done
a log10 genome copy numbers/ml
sheep 15 and 18 were sampled on day 12 not 14
https://doi.org/10.1371/journal.pone.0195302.t002
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FMDV neutralising antibodies up to 21 dpc. Overall there was a greater neutralising antibody
response in the VC animals compared to the UC animals, in line with the expected results fol-
lowing priming of the immune system.
The median time to seroconversion to the structural proteins (determined by ELISA), as
assessed by the Kaplan-Meier time to event analysis, was 1 day in the VC sheep and 12 days in
the UC sheep (Fig 4B). This was a highly significant difference (p = 0. 0.00076).
The comparable time to seroconversion to the non-structural proteins (determined by
ELISA) was 10 days in the VC sheep and 21 days in the UC sheep (Fig 4C), again a highly
Fig 4. (A) Average neutralising antibody titres of the vaccinated (VC) and unvaccinated (UC) contact sheep to the
vaccine virus (A22 Iraq) and the challenge virus (A/VIT/2012). Values represent Log10 of the reciprocal of the highest
dilution of serum that was able to neutralise either A22 Iraq or A/VIT/2012. The assay cut off was 0.9, titres1.2 are
considered positive. Error bars show standard deviation. Time to seroconversion plots estimated by the Kaplan-Meier
method for the vaccinated and non-vaccinated in-contact sheep (B) for the ELISA to the structural protein; and (C) for
the ELISA to the non-structural protein. Note that for both groups of sheep, the start time for the estimate is when the
sheep entered the room housing the donors, and not the day that the vaccine was administered.
https://doi.org/10.1371/journal.pone.0195302.g004
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significant difference (p = 0.00278). However, it must be noted that UC sheep 17 had no signs
of infection, four UC sheep were euthanized between 9 and 12 dpc, and after day 14, sampling
was only done on a weekly basis, skewing the results.
Discussion
Standardised vaccine potency studies quantify efficacy by level of protection from clinical dis-
ease. However, in the context of an outbreak, reduced susceptibility to infection and reduction
in virus excretion is important to reduce transmission [21]. Previous studies have shown vacci-
nation with high payload vaccines can achieve reduction in excretion, including with heterolo-
gous challenge, and with just 4 days between vaccination and challenge [11, 12, 22–27]. More
often, as reported here, vaccination prevents clinical disease but is less effective at preventing
sub-clinical infection and virus excretion [22, 24, 26, 27].
In this study, vaccination with an emergency high payload vaccine (>6PD50/dose) reduced
clinical disease following heterologous challenge by direct contact just 4 dpv, but did not pre-
vent sub-clinical infection or the occurrence of persistent infection. As all UC animals had to
be euthanized by 21 dpc, their carrier status is unavailable for comparison. While there was a
significant difference in the presence or absence of clinical disease and viraemia between the
vaccinated and unvaccinated groups, there was no clear effect of vaccination on virus excre-
tion. However, there were a number of factors that prevent any strong conclusions being
drawn from these results. With direct-contact challenge, the challenge dose, and subsequently
disease severity and virus excretion, is much lower than that seen with CB inoculation. The
number of positive nasal and oral swab samples was small in both the UV and VC groups, and
as the sheep were housed continuously with the donor sheep, we cannot discount positivity
from environmental exposure rather than excretion in some cases. Additionally, sampling of
the UC sheep was not comprehensive due to the requirement for early euthanasia. These
inconclusive results are influenced by the animal to animal variation observed within each
group and the small numbers of animals, which are common limitations when working with
large animals in a BSL3 laboratory where space is often limited. Inherent variation between
outbred animals is to be expected [22, 24, 26, 27].
There can also be differences in disease outcomes due to different animal species, virus
serotype, or challenge method/severity [9, 11, 28, 29]. Coronary band inoculation is widely
used in experiments using sheep, however it does not represent natural infection and in many
cases results in a level of disease severity that is far beyond what sheep would experience in the
field (rev by [30]). Notably, the observed clinical signs in the donor sheep were more severe
than in the UC sheep. An important attribute of direct challenge methods like CB inoculation
is reproducibility. All donors became infected and had similar immune responses, but there
was still significant variation between individual donor sheep in clinical score and in virus
excretion, particularly over the extended 9 day period, likely due to differences in individual
animals’ ability to clear the infection.
This study has highlighted that sheep-to-sheep direct-contact challenge has several limita-
tions in an experimental setting; primarily that the challenge dose and time the animal receives
an infectious dose is unknown. Seroconversion times suggest the contact sheep were infected
at different times over an eight day period, and one UC sheep (sheep 17) did not become
infected. Variation in the amount of virus excreted by donors can influence exposure, although
statistically there was no difference in total excreted virus between the replicate rooms in this
study during the first 6 dpc, which is considered the period when the sheep are most infectious
[20]. Pigs, which excrete larger volumes of virus, have also been used as donors, yet similar
inconsistencies in challenge severity were observed [9, 31]. More recently intranasal
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instillation and aerosol masks have proven effective, reproducible challenge methods [29] Hor-
sington et al., unpublished] that are more ‘natural’ than CB inoculation, and these approaches
should be considered for future studies.
An important consideration for emergency vaccination is the time of challenge following
vaccination. This significantly influences the level of protection, and it has been shown sterile
protection is less common when challenge is just 4 dpv [9, 23, 25, 27, 31]. The onset of disease
in the UC sheep, and time of seroconversion to NSP in all contact sheep, show infection time
post-contact challenge varied, and indicate VC sheep 7 was infected very early (likely the first
day of contact), whereas the remaining vaccinated sheep presumably had additional days for
the development of a protective immune response before being exposed to an infectious dose.
Virus neutralisation titre is generally considered a correlate of protection for FMDV in sheep,
however protection in the absence of detectable neutralising antibodies has been reported [9,
11, 13, 32]. At the time of challenge, all VC sheep had either no detectable VN antibodies or
VN titres considered negative. This may suggest a role of innate immunity in protection. A
role for type I interferons in protection from FMDV has been shown in other species [33, 34],
however in a similar study we found no association between serum interferon levels and pro-
tection in sheep (unpublished). A more detailed investigation into the relationship between
innate immune responses to FMDV and protection in sheep would be beneficial, but was out-
side the scope of this study.
The difference in VN titres to the challenge and vaccine strains in the donor and UC
sheep reflect the calculated r1 value for the virus against the vaccine. Similarly, disparate
VN titres to the two strains were seen in the VC sheep at 5 dpc, with an anamnestic
response from vaccination observed. This was reflected in the significant difference
between the groups in the time to seroconversion to SP in ELISA. While r1 values are
good indicators that a vaccine will work, they are less accurate at showing a vaccine won’t
work, particularly when a high antigen payload is used [11, 35, 36]. Comparing genomic
sequences is equally unreliable [37]. A better understanding of cell-mediated immune
responses, or a combination of approaches is required to more accurately predict heterolo-
gous protection in vitro.
Foot-and-mouth disease continues to be a threat to farmers and livestock industries world-
wide, especially in countries that currently enjoy trade advantages by being FMD-free. If an
outbreak were to occur, the return to freedom must be as quick as possible, and emergency
vaccination can play an important role in this. This report has shown that the A/VIT/15/2012
virus is pathogenic in sheep and, while vaccination with A22 IRQ did not provide sterile
immunity or block persistent infection when sheep were challenged just 4 dpv, it was effective
at reducing clinical disease and viraemia, supporting the use of this vaccine in an outbreak
with A/VIT/15/2012 or similar viruses.
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